fda compounding semaglutide enforcement november 2025 glp-1 news The FDA has released new guidance for providers prescribing GLP-1 Shortage = Over FDA Moves to Restrict Mass-Marketed

Retatrutide has shown favorable effects on various cardiovascular parameters, making it a valuable tool in managing cardiovascular comorbidities

If you're under 50 with no risk factors, screening may not be necessary before starting GLP-1 therapy, but discussing personal risk with your PlexusDx clinical team ensures appropriate monitoring

Our testers found that the printing on their oral syringes faded quickly from exposure to the medicine, which eventually made it impossible to measure doses accurately

10.1046/j.1468-1331.2002.00384.x Eur

Adverse events followed the same gastrointestinal pattern: diarrhea (30.1% / 24.4% at 9 / 12 mg vs 8.7% on placebo), nausea (21.7% / 22.4% vs 5.8%) and dysesthesia (6.4% / 6.4% vs 1.3%)

A few things: aggressive agitation (shaking), exposure to the wrong pH, or using a non-sterile diluent that introduces contaminants